Back to Journals » OncoTargets and Therapy » Volume 11

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy

Total article views   Abstract views HTML views PDF downloads Totals
5,602 Dovepress* 3,779 402+ 379 4,181
PubMed Central* 0 1,421 287 1,421
Totals 3,779 1,823 666 5,602
*Since 14 December 2018
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
6 0 0 0 3 3

View citations on PubMed Central and Google Scholar